Arhgdia Mouse shRNA Plasmid (Locus ID 192662)
CAT#: TL506187
Arhgdia - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 5,740.00
Cited in 1 publication. |
Product images
CNY 4,070.00
Specifications
Product Data | |
Product Name | Arhgdia Mouse shRNA Plasmid (Locus ID 192662) |
Locus ID | 192662 |
UniProt ID | Q99PT1 |
Synonyms | 5330430M07Rik; Gdi-1; Rho-GDI; RhoDGI; RhoGDI-1 |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | Arhgdia - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 192662). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | BC004732, BC086755, NM_133796, NM_133796.2, NM_133796.3, NM_133796.4, NM_133796.5, NM_133796.6, NM_133796.7, NM_001363425, NM_133796.8 |
Summary | Controls Rho proteins homeostasis. Regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the dissociation of GDP from them, and the subsequent binding of GTP to them. Retains Rho proteins such as CDC42, RAC1 and RHOA in an inactive cytosolic pool, regulating their stability and protecting them from degradation. Actively involved in the recycling and distribution of activated Rho GTPases in the cell, mediates extraction from membranes of both inactive and activated molecules due its exceptionally high affinity for prenylated forms. Through the modulation of Rho proteins, may play a role in cell motility regulation. In glioma cells, inhibits cell migration and invasion by mediating the signals of SEMA5A and PLXNB3 that lead to inactivation of RAC1.[UniProtKB/Swiss-Prot Function] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Differentially expressed proteins in ER+ MCF7 and ER- MDA- MB-231 human breast cancer cells by RhoGDI-α silencing and overexpression.
,null,
Asian Pacific journal of cancer prevention : APJCP
,PubMed ID 24815488
[Arhgdia]
|
Documents
Product Manuals |
FAQs |
SDS |
其它Arhgdia产品